Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZGHUMSC001 is an investigational allogeneic cell therapy consisting of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs). Developed by Guizhou Zhongguan Biotechnology, it is specifically designed for the treatment of knee osteoarthritis. The therapy is administered via intra-articular injection, where the MSCs are intended to modulate the local immune response and reduce chronic inflammation within the joint environment. By secreting a variety of paracrine factors, including cytokines and growth factors, ZGHUMSC001 aims to alleviate joint pain, improve physical function, and potentially support the preservation or repair of articular cartilage in patients suffering from degenerative joint disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ZGHUMSC001.